Recent Quotes (30 days)

You have no recent quotes
chg | %

AstraZeneca plc news

   Watch this stock
Showing stories 1 - 10 of about 61   

Articles published

AZN 4,120.00 +36.00 (0.88%)
price chart
AstraZeneca Is Undervalued
AstraZeneca plc is a global biopharmaceutical company. AstraZeneca discovers, develops and commercializes prescription medicines for six areas of healthcare: Cardiovascular, Gastrointestinal, Infection, Neuroscience, Oncology, and Respiratory and ...
AstraZeneca Antitrust Fine Should Stand, EU Court Aide Says
May 15 (Bloomberg) -- AstraZeneca Plc, the U.K.'s second-biggest drugmaker, shouldn't get a further reduction in an antitrust fine of 52.5 million euros ($67.5 million), an adviser to the European Union's highest court said.
Amylin Said to Attract Interest From Pfizer, AstraZeneca
May 15 (Bloomberg) -- Amylin Pharmaceuticals Inc. has lured suitors such as Pfizer Inc., AstraZeneca Plc and Sanofi, which signed confidentiality agreements on the drugmaker's sale process, said people familiar with the matter.
AstraZeneca in experimental drugs push
AstraZeneca plans to seal several new deals this year to fill its flagging pipeline of experimental medicines, which may be funded jointly with private investors.
Aviva chief resigns after shareholder uprising
The resignation of Moss followed the high-profile exits of Sly Bailey from Trinity Mirror and David Brennan from AstraZeneca last week as a result of shareholder hostility. Aviva shares, which have fallen a third in a year, were up 4% on the news. Lord ...
UK Pay Protests Oust Aviva Chief  Wall Street Journal
Shareholder spring: After the unseating of big beasts, no overpaid executive ...
Sly Bailey of Trinity Mirror and David Brennan of AstraZeneca have been defenestrated due to a toxic mix of large rewards and lacklustre returns.
Stock to Watch: British American Tobacco
This article is for information and discussion purposes only and does not form a recommendation to invest or otherwise. The value of an investment may fall.
Boards wake up to a shareholder spring
Two weeks ago David Brennan, chief executive of AstraZeneca, bowed to pressure from the pharmaceutical group's top shareholders and stepped down at the annual meeting.
Risk and reward: The world's most dangerous business locations
Convenience is not a priority when it comes to commodities. Drilling and exploration often takes place in war-torn, risky environments and none more so than Somalia.
EU Joins Widening Push to Find New Antibiotics
"Antibiotics are fundamental for the practice of medicine," says John Rex, vice-president of clinical infection at AstraZeneca PLC." Without them you cannot get your heart valve replaced, take care of a premature infant, get your cancer treated, or ...